FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * ARMISTICE CAPITAL, LLC 2. Date of Event Requiring Statement (MM/DD/YYYY)
7/6/2020 

3. Issuer Name and Ticker or Trading Symbol TENAX THERAPEUTICS, INC. [TENX]
(Last)       (First)       (Middle)
510 MADISON AVENUE, 7TH FLOOR, 
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)
NEW YORK, NY 10022      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.0001 par value per share  1523611  D (1)  
Common Stock, $0.0001 par value per share  1523611  I  See Footnote 1 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Purchase Warrants  3/13/2020 (2) 9/13/2025  Common Stock  2360313  $1.04  D (1)  
Common Stock Purchase Warrants  3/13/2020 (2) 9/13/2025  Common Stock  2360313  $1.04  I  See Footnote (1)
Common Stock Purchase Warrants  12/11/2018 (2) 12/11/2020  Common Stock  2072538  $1.93  D (1)  
Common Stock Purchase Warrants  12/11/2018 (2) 12/11/2020  Common Stock  2072538  $1.93  I  See Footnote (1)
Common Stock Purchase Warrants  12/11/2018 (2) 12/11/2023  Common Stock  2072538  $1.93  D (1)  
Common Stock Purchase Warrants  12/11/2018 (2) 12/11/2023  Common Stock  2072538  $1.93  I  See Footnote (1)
Pre-Funded Common Stock Purchase Warrants  7/6/2020 (3)  (4) Common Stock  5260005  $0.0001  D (1)  
Pre-Funded Common Stock Purchase Warrants  7/6/2020 (3)  (4) Common Stock  5260005  $0.0001  I  See Footnote (1)
Series B Common Stock Purchase Warrants  7/6/2020 (3) 1/6/2026  Common Stock  3175924  $0.903  D (1)  
Series B Common Stock Purchase Warrants  7/6/2020 (3) 1/6/2026  Common Stock  3175924  $0.903  I  See Footnote (1)
Series C Common Stock Purchase Warrants  7/6/2020 (3) 1/6/2026  Common Stock  4607692  $0.903  D (1)  
Series C Common Stock Purchase Warrants  7/6/2020 (3) 1/6/2026  Common Stock  4607692  $0.903  I  See Footnote (1)

Explanation of Responses:
(1)  The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(2)  These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the "Shares") following such exercise.
(3)  These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise.
(4)  These warrants do not expire.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022

X

Armistice Capital Master Fund Ltd.
C/O DMS CORPORATE SERVICES LTD.
20 GENESIS CLOSE, P.O. BOX 314
GRAND CAYMAN, E9 KY1-1104

X

Boyd Steven
C/O ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022

X


Signatures
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member 7/16/2020
**Signature of Reporting Person Date
Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Director 7/16/2020
**Signature of Reporting Person Date
/s/ Steven Boyd 7/16/2020
**Signature of Reporting Person Date
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Tenax Therapeutics Charts.
Tenax Therapeutics (NASDAQ:TENX)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Tenax Therapeutics Charts.